S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
AMD Results Are No Reason To Buy Semiconductors... Yet
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:SMFR

Sema4 - SMFR Stock Forecast, Price & News

$0.42
+0.02 (+4.94%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.39
▼
$0.43
50-Day Range
$0.22
▼
$0.53
52-Week Range
$0.22
▼
$4.67
Volume
3.41 million shs
Average Volume
2.37 million shs
Market Capitalization
$160.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.67

Sema4 MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
527.7% Upside
$2.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$2.72 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.88) to ($0.53) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

684th out of 1,053 stocks

Health Services Industry

8th out of 12 stocks

See Top Rated MarketRank™ Stocks Here

SMFR stock logo

About Sema4 (NASDAQ:SMFR) Stock

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

Receive SMFR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sema4 and its competitors with MarketBeat's FREE daily newsletter.

SMFR Stock News Headlines

January 29, 2023 | americanbankingnews.com
Sema4 Holdings Corp. (NASDAQ:SMFR) Given Consensus Recommendation of "Moderate Buy" by Analysts
January 9, 2023 | finance.yahoo.com
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
December 30, 2022 | finance.yahoo.com
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 5, 2022 | finance.yahoo.com
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
November 28, 2022 | reuters.com
Sema4 Holdings Corp
November 14, 2022 | finance.yahoo.com
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
November 4, 2022 | finance.yahoo.com
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
February 2, 2023 | Tradewins (Ad)
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
October 31, 2022 | finance.yahoo.com
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
October 27, 2022 | finance.yahoo.com
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
October 26, 2022 | finance.yahoo.com
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
October 20, 2022 | finance.yahoo.com
SMFR LAWSUIT ALERT: Levi & Korsinsky Notifies Sema4 Holdings, Corp. Investors of a Class Action Lawsuit and Upcoming Deadline
October 20, 2022 | benzinga.com
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Sema4 Holdings Corp. Investors With Losses to Secure Counse - Benzinga
October 19, 2022 | benzinga.com
CLASS ACTION UPDATE for NIO, SMFR and BCS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Be - Benzinga
October 19, 2022 | benzinga.com
DEADLINE ALERT for TSP, SMFR, TWTR, PLTR: Law Offices of Howard G. Smith Reminds Investors of Class Actio - Benzinga
October 19, 2022 | benzinga.com
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses - Benzinga
October 18, 2022 | benzinga.com
ROSEN, Top Ranked Investor Counsel, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Im - Benzinga
October 18, 2022 | benzinga.com
SEMA4 HOLDINGS CORP. (NASDAQ: SMFR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Invest - Benzinga
October 17, 2022 | benzinga.com
ROSEN, A LEADING LAW FIRM, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important D - Benzinga
October 17, 2022 | globenewswire.com
SMFR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Sema4 Holdings (SMFR) Investors with Significant Losses to Contact Firm's Attorneys, Securities Class Action Pending - GlobeNewswire
October 16, 2022 | benzinga.com
ROSEN, A LEADING LAW FIRM, Encourages Sema4 Holdings Corp. Investors with Losses to Secure Counsel Before - Benzinga
October 13, 2022 | benzinga.com
Sema4 Study Demonstrates The Utility Of Exome Sequencing For Diagnosing Autism Spectrum Disorders; Research From 19000 Patients With Autism Spectrum Disorders Found ~90% Had Prior Negative Tests - Sema4 Holdings (NASDAQ:SMFR) - Benzinga
October 13, 2022 | finance.yahoo.com
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
October 9, 2022 | globenewswire.com
ROSEN, A TOP RANKED FIRM, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SMFR, SMFRW - GlobeNewswire
October 9, 2022 | benzinga.com
ROSEN, A TOP RANKED FIRM, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important De - Benzinga
October 8, 2022 | businesswire.com
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Sema4 Holdings Corp. (SMFR; SMFRW) Investors and Encourages Investors to Contact the Firm Before November 7, 2022 - businesswire.com
See More Headlines
Receive SMFR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sema4 and its competitors with MarketBeat's FREE daily newsletter.

SMFR Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Health services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SMFR
CUSIP
N/A
CIK
1818331
Web
cmlifesciencesspac.com
Phone
800-298-6470
Fax
N/A
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.67
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+527.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-245,390,000.00
Net Margins
-121.31%
Pretax Margin
-142.57%
Return on Equity
-53.31%
Return on Assets
-36.04%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
1.89
Quick Ratio
1.62

Sales & Book Value

Annual Sales
$212.20 million
Price / Sales
0.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
0.26

Miscellaneous

Outstanding Shares
377,249,000
Free Float
N/A
Market Cap
$160.26 million
Optionable
Optionable
Beta
1.61

Key Executives

  • Mr. Jason Ryan (Age 49)
    Exec. Chair of the Board
    Comp: $30k
  • Mr. Isaac RoMr. Isaac Ro
    Consultant
  • Ms. Katherine A. Stueland (Age 47)
    CEO & Director
  • Mr. Kevin Feeley
    Sr. VP of Operations & CFO
  • Mr. Robert Sebra Ph.D.
    VP of Technology Devel.
  • Dr. Matthew Davis Ph.D.
    Chief Technology & Product Officer
  • Dr. Gustavo Stolovitzky Ph.D.
    Chief Science Officer
  • Mr. Murali Mani
    Chief Compliance & Privacy Officer
  • Ms. Karen White (Age 52)
    Chief People Officer
  • Mr. Kareem M. Saad (Age 43)
    Chief Transformation Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SMFR Stock - Frequently Asked Questions

Should I buy or sell Sema4 stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sema4 in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SMFR shares.
View SMFR analyst ratings or view top-rated stocks.

What is Sema4's stock price forecast for 2023?

5 equities research analysts have issued 12 month price objectives for Sema4's shares. Their SMFR share price forecasts range from $1.00 to $5.00. On average, they predict the company's stock price to reach $2.67 in the next year. This suggests a possible upside of 527.7% from the stock's current price.
View analysts price targets for SMFR or view top-rated stocks among Wall Street analysts.

How have SMFR shares performed in 2023?

Sema4's stock was trading at $0.2638 on January 1st, 2023. Since then, SMFR stock has increased by 61.0% and is now trading at $0.4248.
View the best growth stocks for 2023 here.

When is Sema4's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our SMFR earnings forecast.

How were Sema4's earnings last quarter?

Sema4 Holdings Corp. (NASDAQ:SMFR) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.01. The business had revenue of $83.23 million for the quarter, compared to the consensus estimate of $76.60 million. Sema4 had a negative net margin of 121.31% and a negative trailing twelve-month return on equity of 53.31%.

What guidance has Sema4 issued on next quarter's earnings?

Sema4 updated its FY 2023 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205.00 million-$220.00 million, compared to the consensus revenue estimate of $217.84 million.

What is Sema4's stock symbol?

Sema4 trades on the NASDAQ under the ticker symbol "SMFR."

Who are Sema4's major shareholders?

Sema4's stock is owned by many different retail and institutional investors. Top institutional investors include Trellus Management Company LLC (0.29%). Insiders that own company stock include Anthony Prentice, Daniel Emmett Clark, Eric Schadt, Isaac Ro, James Coffin, Jason Ryan, Kareem Saad, Karen Ann White, Katherine Stueland, Keith A Meister, Kevin Feeley, Richard Miao, Shawn Assad and Tactical Opportunit Blackstone.
View institutional ownership trends.

How do I buy shares of Sema4?

Shares of SMFR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sema4's stock price today?

One share of SMFR stock can currently be purchased for approximately $0.42.

How much money does Sema4 make?

Sema4 (NASDAQ:SMFR) has a market capitalization of $160.26 million and generates $212.20 million in revenue each year. The company earns $-245,390,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does Sema4 have?

The company employs 1,200 workers across the globe.

How can I contact Sema4?

Sema4's mailing address is 667 Madison Avenue, New York NY, 10065. The official website for the company is cmlifesciencesspac.com. The company can be reached via phone at 800-298-6470 or via email at investors@sema4.com.

This page (NASDAQ:SMFR) was last updated on 2/2/2023 by MarketBeat.com Staff